CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression

Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254 CrossRefPubMed Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi:10.​3322/​caac.​21254 CrossRefPubMed

Zurück zum Zitat Mostaghel EA, Montgomery B, Nelson PS (2009) Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 27(3):251–257. doi:10.1016/j.urolonc.2009.03.016 CrossRefPubMedPubMedCentral Mostaghel EA, Montgomery B, Nelson PS (2009) Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 27(3):251–257. doi:10.​1016/​j.​urolonc.​2009.​03.​016 CrossRefPubMedPubMedCentral

Zurück zum Zitat Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33–39. doi:10.1038/nm972 CrossRefPubMed Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33–39. doi:10.​1038/​nm972 CrossRefPubMed

Zurück zum Zitat de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. doi:10.1056/NEJMoa1014618 CrossRefPubMedPubMedCentral de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. doi:10.​1056/​NEJMoa1014618 CrossRefPubMedPubMedCentral

Zurück zum Zitat Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433. doi:10.1056/NEJMoa1405095 CrossRefPubMedPubMedCentral Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433. doi:10.​1056/​NEJMoa1405095 CrossRefPubMedPubMedCentral

Zurück zum Zitat De Maeseneer DJ, Van Praet C, Lumen N, Rottey S (2015) Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. Urol Oncol 33(7):310–321. doi:10.1016/j.urolonc.2015.01.008 CrossRefPubMed De Maeseneer DJ, Van Praet C, Lumen N, Rottey S (2015) Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. Urol Oncol 33(7):310–321. doi:10.​1016/​j.​urolonc.​2015.​01.​008 CrossRefPubMed

Zurück zum Zitat Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228. doi:10.1016/j.cell.2015.05.001 CrossRefPubMedPubMedCentral Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228. doi:10.​1016/​j.​cell.​2015.​05.​001 CrossRefPubMedPubMedCentral

Zurück zum Zitat Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447–4454. doi:10.1158/0008-5472.can-08-0249 CrossRefPubMedPubMedCentral Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447–4454. doi:10.​1158/​0008-5472.​can-08-0249 CrossRefPubMedPubMedCentral

Zurück zum Zitat Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV (2016) Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7. World J Urol 34(5):633–639. doi:10.1007/s00345-015-1674-5 CrossRefPubMed Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV (2016) Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7. World J Urol 34(5):633–639. doi:10.​1007/​s00345-015-1674-5 CrossRefPubMed

Zurück zum Zitat Nakazawa M, Antonarakis ES, Luo J (2014) Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 5 (5):265–273. doi:10.1007/s12672-014-0190-1 CrossRefPubMedPubMedCentral Nakazawa M, Antonarakis ES, Luo J (2014) Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 5 (5):265–273. doi:10.​1007/​s12672-014-0190-1 CrossRefPubMedPubMedCentral

Zurück zum Zitat Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305–2313. doi:10.1158/0008-5472.can-08-3795 CrossRefPubMedPubMedCentral Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305–2313. doi:10.​1158/​0008-5472.​can-08-3795 CrossRefPubMedPubMedCentral

Zurück zum Zitat Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73(2):483–489. doi:10.1158/0008-5472.CAN-12-3630 CrossRefPubMed Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73(2):483–489. doi:10.​1158/​0008-5472.​CAN-12-3630 CrossRefPubMed

Zurück zum Zitat Gietz RD, Graham KC, Litchfield DW (1995) Interactions between the subunits of casein kinase II. J Biol Chem 270(22):13017–13021CrossRefPubMed Gietz RD, Graham KC, Litchfield DW (1995) Interactions between the subunits of casein kinase II. J Biol Chem 270(22):13017–13021CrossRefPubMed

Zurück zum Zitat Montenarh M (2014) Protein kinase CK2 and angiogenesis. Adv Clin Exp Med 23 (2):153–158CrossRefPubMed Montenarh M (2014) Protein kinase CK2 and angiogenesis. Adv Clin Exp Med 23 (2):153–158CrossRefPubMed

Zurück zum Zitat Trembley JH, Wang G, Unger G, Slaton J, Ahmed K (2009) Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci CMLS 66 (11–12):1858–1867. doi:10.1007/s00018-009-9154-y CrossRefPubMed Trembley JH, Wang G, Unger G, Slaton J, Ahmed K (2009) Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci CMLS 66 (11–12):1858–1867. doi:10.​1007/​s00018-009-9154-y CrossRefPubMed

Zurück zum Zitat Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K (1994) Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 24(1):11–16CrossRefPubMed Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K (1994) Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 24(1):11–16CrossRefPubMed

Zurück zum Zitat Yoo JY, Lim BJ, Choi HK, Hong SW, Jang HS, Kim C, Chun KH, Choi KC, Yoon HG (2013) CK2-NCoR signaling cascade promotes prostate tumorigenesis. Oncotarget 4(7):972–983CrossRefPubMedPubMedCentral Yoo JY, Lim BJ, Choi HK, Hong SW, Jang HS, Kim C, Chun KH, Choi KC, Yoon HG (2013) CK2-NCoR signaling cascade promotes prostate tumorigenesis. Oncotarget 4(7):972–983CrossRefPubMedPubMedCentral

Zurück zum Zitat Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H (2012) Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate 72(13):1423–1430. doi:10.1002/pros.22493 CrossRefPubMed Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H (2012) Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate 72(13):1423–1430. doi:10.​1002/​pros.​22493 CrossRefPubMed

Zurück zum Zitat Hessenauer A, Montenarh M, Gotz C (2003) Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22(6):1263–1270PubMed Hessenauer A, Montenarh M, Gotz C (2003) Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22(6):1263–1270PubMed

Zurück zum Zitat Krause WC, Shafi AA, Nakka M, Weigel NL (2014) Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 54:49–59. doi:10.1016/j.biocel.2014.06.013 CrossRefPubMedPubMedCentral Krause WC, Shafi AA, Nakka M, Weigel NL (2014) Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 54:49–59. doi:10.​1016/​j.​biocel.​2014.​06.​013 CrossRefPubMedPubMedCentral

Zurück zum Zitat Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62(22):6770–6778PubMed Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62(22):6770–6778PubMed

Zurück zum Zitat Jaksch C, Thams P (2014) A critical role for CK2 in cytokine-induced activation of NFkappaB in pancreatic beta cell death. Endocr 47(1):117–128. doi:10.1007/s12020-013-0133-6 CrossRef Jaksch C, Thams P (2014) A critical role for CK2 in cytokine-induced activation of NFkappaB in pancreatic beta cell death. Endocr 47(1):117–128. doi:10.​1007/​s12020-013-0133-6 CrossRef

Zurück zum Zitat Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2014) Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene. doi:10.1038/onc.2014.302 Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2014) Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene. doi:10.​1038/​onc.​2014.​302

Zurück zum Zitat Chatterjee A, Chatterjee U, Ghosh MK (2013) Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer. Cell Death Dis 4:e543. doi:10.1038/cddis.2013.63 CrossRefPubMedPubMedCentral Chatterjee A, Chatterjee U, Ghosh MK (2013) Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer. Cell Death Dis 4:e543. doi:10.​1038/​cddis.​2013.​63 CrossRefPubMedPubMedCentral

Zurück zum Zitat Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In vitro Cell Dev Biol Anim 35 (7):403–409. doi:10.1007/s11626-999-0115-4 CrossRefPubMed Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In vitro Cell Dev Biol Anim 35 (7):403–409. doi:10.​1007/​s11626-999-0115-4 CrossRefPubMed

Zurück zum Zitat Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790. doi:10.1126/science.1168175 CrossRefPubMedPubMedCentral Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790. doi:10.​1126/​science.​1168175 CrossRefPubMedPubMedCentral

Zurück zum Zitat Yamashita S, Lai K-P, Chuang K-L, Xu D, Miyamoto H, Tochigi T, Pang S-T, Li L, Arai Y, Kung H-J, Yeh S, Chang C (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14(1):74–N12. doi:10.1593/neo.111436 CrossRefPubMedPubMedCentral Yamashita S, Lai K-P, Chuang K-L, Xu D, Miyamoto H, Tochigi T, Pang S-T, Li L, Arai Y, Kung H-J, Yeh S, Chang C (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14(1):74–N12. doi:10.​1593/​neo.​111436 CrossRefPubMedPubMedCentral

Zurück zum Zitat Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA (2007) Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67(21):10296–10303. doi:10.1158/0008-5472.can-07-2173 CrossRefPubMed Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA (2007) Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67(21):10296–10303. doi:10.​1158/​0008-5472.​can-07-2173 CrossRefPubMed

Zurück zum Zitat Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, Matusik RJ (2013) Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PloS One 8(4):e60983. doi:10.1371/journal.pone.0060983 CrossRefPubMedPubMedCentral Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, Matusik RJ (2013) Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PloS One 8(4):e60983. doi:10.​1371/​journal.​pone.​0060983 CrossRefPubMedPubMedCentral

Zurück zum Zitat Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8):2715–2730. doi:10.1172/jci41824 CrossRefPubMedPubMedCentral Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8):2715–2730. doi:10.​1172/​jci41824 CrossRefPubMedPubMedCentral